GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bolt Biotherapeutics Inc (STU:6LP) » Definitions » Price-to-Free-Cash-Flow

Bolt Biotherapeutics (STU:6LP) Price-to-Free-Cash-Flow : N/A (As of Dec. 15, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Bolt Biotherapeutics Price-to-Free-Cash-Flow?

As of today (2024-12-15), Bolt Biotherapeutics's share price is €0.495. Bolt Biotherapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2024 was €-1.47. Hence, Bolt Biotherapeutics's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Bolt Biotherapeutics's Price-to-Free-Cash-Flow or its related term are showing as below:

STU:6LP's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 35.18
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Bolt Biotherapeutics's Free Cash Flow per Share for the three months ended in Sep. 2024 was €-0.33. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was €-1.47.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -5.10% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -9.20% per year.

During the past 6 years, Bolt Biotherapeutics's highest 3-Year average Free Cash Flow per Share Growth Rate was -3.10% per year. The lowest was -18.40% per year. And the median was -5.10% per year.


Bolt Biotherapeutics Price-to-Free-Cash-Flow Historical Data

The historical data trend for Bolt Biotherapeutics's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bolt Biotherapeutics Price-to-Free-Cash-Flow Chart

Bolt Biotherapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial - - - - -

Bolt Biotherapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Bolt Biotherapeutics's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Bolt Biotherapeutics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bolt Biotherapeutics's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bolt Biotherapeutics's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Bolt Biotherapeutics's Price-to-Free-Cash-Flow falls into.



Bolt Biotherapeutics Price-to-Free-Cash-Flow Calculation

Bolt Biotherapeutics's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=0.495/-1.472
=N/A

Bolt Biotherapeutics's Share Price of today is €0.495.
Bolt Biotherapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.47.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Bolt Biotherapeutics  (STU:6LP) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Bolt Biotherapeutics Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Bolt Biotherapeutics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Bolt Biotherapeutics Business Description

Traded in Other Exchanges
Address
900 Chesapeake Drive, Redwood, CA, USA, 94063
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.

Bolt Biotherapeutics Headlines

No Headlines